Proteome Changes Associated with the VEGFR Pathway and Immune System in Diabetic Macular Edema Patients at Different Diabetic Retinopathy Stages

Abstract Purpose Diabetic macular edema (DME) is a major cause of vision loss in all stages of diabetic retinopathy (DR). However, there is limited recognition of aqueous humor (AH) proteome profiles of DME patients at different DR stages. In this study, we aimed to investigate the AH proteome changes between DME patients at the nonproliferative diabetic retinopathy (NPDR) stage and those at the proliferative diabetic retinopathy (PDR) stage. Methods A label-free data-independent acquisition based liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis was performed to profile the abundances of AH proteins in 73 eyes from DME patients at different DR stages. Enzyme-linked immunosorbent assay (ELISA) was used to confirm the proteomics results with AH samples from non-diabetic patients and DME patients at the NPDR or PDR stage. Results LC-MS/MS results showed significantly changed expression of 308 proteins between DME patients in the NPDR and PDR groups. Compared to the NPDR group, the proteins relatively up-regulated in the PDR group are involved in the immune system and/or negative regulation of the cell cycle, while proteins relatively down-regulated in the PDR group are associated with the vascular endothelial growth factor receptor (VEGFR) pathway and/or metabolism. ELISA results further verified the proteomic result of down-regulated expression of the immune-associated protein cystatin C (CST3) in the PDR group compared to that in the NPDR and non-diabetic groups. Conclusions In this study, we reported for the first time the decreased abundances of AH proteins associated with the VEGFR pathway and both down- and up-regulated expression of AH proteins associated with the immune system in the PDR group compared to that in the NPDR group. Furthermore, we found negative correlations of immune-associated protein, CST3 concentration in AH with DR severity and central retinal thickness, suggesting CST3 as a promising target independent of the VEGFR pathway in DME-involved DR treatment.

[1]  F. Rossato,et al.  Novel engineered, membrane‐tethered VEGF‐A variants promote formation of filopodia, proliferation, survival, and cord or tube formation by endothelial cells via persistent VEGFR2/ERK signaling and activation of CDC42/ROCK pathways , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Hongyang Wang,et al.  Cdc42 functions as a regulatory node for tumour‐derived microvesicle biogenesis , 2021, Journal of extracellular vesicles.

[3]  B. Honoré,et al.  Aqueous Fibronectin Correlates With Severity of Macular Edema and Visual Acuity in Patients With Branch Retinal Vein Occlusion: A Proteome Study , 2020, Investigative ophthalmology & visual science.

[4]  H. Mott,et al.  Activation of STAT transcription factors by the Rho-family GTPases , 2020, Biochemical Society transactions.

[5]  J. Chhablani,et al.  Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant , 2020, Acta ophthalmologica.

[6]  U. Schmidt-Erfurth,et al.  An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification , 2019, European journal of ophthalmology.

[7]  I. Fabregat,et al.  Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-β-induced epithelial to amoeboid transition , 2019, Cancer letters.

[8]  A. Loewenstein,et al.  Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naïve diabetic macular oedema after PPV with ILM peeling , 2019, British Journal of Ophthalmology.

[9]  A. Loewenstein,et al.  The Role of Steroids in the Management of Diabetic Macular Edema , 2019, Ophthalmic Research.

[10]  Jennifer K. Sun,et al.  Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. , 2019, Ophthalmology.

[11]  J. Chhablani,et al.  DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study , 2019, Retina.

[12]  A. Loewenstein,et al.  UNDERDIAGNOSED OPTIC DISK PIT MACULOPATHY: Spectral Domain Optical Coherence Tomography Features For Accurate Diagnosis. , 2019, Retina.

[13]  M. Maia,et al.  Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience , 2018, Ophthalmologica.

[14]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[15]  J. Chhablani,et al.  Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study , 2018, PloS one.

[16]  Qianyi Lu,et al.  Quantitative proteomics analysis of vitreous body from type 2 diabetic patients with proliferative diabetic retinopathy , 2018, BMC Ophthalmology.

[17]  A. Loewenstein,et al.  Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’ , 2018, Acta Diabetologica.

[18]  Min Zhao,et al.  Mechanisms of macular edema: Beyond the surface , 2017, Progress in Retinal and Eye Research.

[19]  A. Loewenstein,et al.  OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. , 2017, Ophthalmology.

[20]  Ting Zhang,et al.  Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy. , 2017, Investigative ophthalmology & visual science.

[21]  J. Qin,et al.  A Bioinformatic Algorithm for Analyzing Cell Signaling Using Temporal Proteomic Data , 2017, Proteomics.

[22]  Jun Qin,et al.  Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis , 2017, Nature Biotechnology.

[23]  B. Honoré,et al.  A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders , 2017, International journal of molecular sciences.

[24]  Tien Yin Wong,et al.  Diabetic macular oedema. , 2017, The lancet. Diabetes & endocrinology.

[25]  Jason Hsu,et al.  Quantification of Diabetic Macular Ischemia Using Optical Coherence Tomography Angiography and Its Relationship with Visual Acuity. , 2017, Ophthalmology.

[26]  A. Ho,et al.  Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. , 2016, American journal of ophthalmology.

[27]  Emma J. Reid,et al.  Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications. , 2016, Journal of the American Society of Nephrology : JASN.

[28]  Fitsum Tamene,et al.  Quantitative Proteomics Analysis of Vitreous Humor from Diabetic Retinopathy Patients. , 2015, Journal of proteome research.

[29]  Michael J MacCoss,et al.  Multiplexed peptide analysis using data-independent acquisition and Skyline , 2015, Nature Protocols.

[30]  L. Aiello,et al.  Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema , 2015, Diabetes.

[31]  Ludovic C. Gillet,et al.  Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps , 2015, Nature Medicine.

[32]  R. Spaide,et al.  Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. , 2015, JAMA ophthalmology.

[33]  W. Jia,et al.  Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population. , 2014, European journal of endocrinology.

[34]  José Cunha-Vaz,et al.  Phenotypes and biomarkers of diabetic retinopathy , 2014, Progress in Retinal and Eye Research.

[35]  Ben C. Collins,et al.  A tool for the automated, targeted analysis of data-independent acquisition MS-data: OpenSWATH , 2014 .

[36]  F. Wang,et al.  Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry. , 2013, Experimental eye research.

[37]  C. Clar,et al.  Current treatments in diabetic macular oedema: systematic review and meta-analysis , 2013, BMJ Open.

[38]  Y. Chou,et al.  Proteomic analysis and identification of aqueous humor proteins with a pathophysiological role in diabetic retinopathy. , 2012, Journal of proteomics.

[39]  D. Antonetti,et al.  Protein Kinase Cβ Phosphorylates Occludin Regulating Tight Junction Trafficking in Vascular Endothelial Growth Factor–Induced Permeability In Vivo , 2012, Diabetes.

[40]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[41]  Ludovic C. Gillet,et al.  Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis* , 2012, Molecular & Cellular Proteomics.

[42]  Characterisation of the vitreous proteome in proliferative diabetic retinopathy , 2012, Proteome Science.

[43]  Jennifer K. Sun,et al.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.

[44]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[45]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[46]  N. Komori,et al.  Proteome profiling of vitreoretinal diseases by cluster analysis , 2008, Proteomics. Clinical applications.

[47]  L. Aiello,et al.  Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. , 2008, Journal of proteome research.

[48]  K. Park,et al.  Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients , 2007, Proteomics.

[49]  G. Davis,et al.  The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. , 2002, Journal of cell science.

[50]  B Kirchhof,et al.  Leukocyte-mediated endothelial cell injury and death in the diabetic retina. , 2001, The American journal of pathology.

[51]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[52]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.